U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

RSV is the most harmful respiratory illness for young infants, says Dr. Jeffrey Pernica, a professor in the Department of ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and ...

It's called Respiratory Virus Dashboard, replacing the old COVID-19 dashboard. This new tool allows users to explore data for ...

Now that it’s autumn, many will be dodging illnesses like COVID, Influenza, Respiratory Syncytial Virus (RSV), and other ...